FDA approves Junshi, Coherus’ PD-1 toripalimab for nasopharyngeal carcinoma - Endpoints News
endpts.comSubmitted by endpointsnews6292 in business
The first Chinese PD-1 is coming to the US market, as the FDA approves toripalimab in recurrent or metastatic nasopharyngeal carcinoma (NPC) across all lines of treatment. Junshi Biosciences — which back in 2018 became the first drugmaker to win approval in C…